X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
Details:
SJP-002C (ketotifen) world most potent, orally available anti-inflammatory a person could obtain for a mild to moderate coronavirus infection, Sen-Jam's investigational therapeutic for treatment of COVID-19, SJP-002C is now actively enrolling patients for their clinical trial.
Lead Product(s): Ketotifen Fumarate,Indomethacin
Therapeutic Area: Infections and Infectious Diseases Product Name: SJP-002C
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: KVK-TECH, INC.
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 06, 2022
Details:
KVK will have exclusive manufacturing and supply rights for the product SJP-002C (Ketotifen) in the US. Sen-Jam will utilize the finished formulation and CMC report to enter licensing deals with contracting manufacturing companies (CMOs) globally.
Lead Product(s): Ketotifen Fumarate,Indomethacin
Therapeutic Area: Infections and Infectious Diseases Product Name: SJP-002C
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: KVK-TECH, INC.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 05, 2022
Details:
Sen-Jam Pharmaceutical has entered a development, manufacturing, distribution, and license agreement with KVK-Tech. This is a monumental milestone for the company and great news for their promising oral COVID-19 treatment, SJP-002C.
Lead Product(s): Ketotifen Fumarate,Indomethacin
Therapeutic Area: Infections and Infectious Diseases Product Name: SJP-002C
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: KVK-TECH, INC.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 22, 2022
Details:
The collaboration received official approval this past Friday from the Nepal Health Research Council and is now commencing Phase II Clinical Trials of SJP-002C, for a novel oral therapy to mitigate the symptoms and hospitalizations associated with COVID-19.
Lead Product(s): Ketotifen Fumarate,Indomethacin
Therapeutic Area: Infections and Infectious Diseases Product Name: SJP-002C
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Duke University School of Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 22, 2022
Details:
EM-100 is an eye drop to ease itchy eyes from allergic conjunctivitis. Eton's partner has not yet received a communication from the U.S. Food and Drug Administration (FDA) regarding its decision on the review of EM-100.
Lead Product(s): Ketotifen Fumarate
Therapeutic Area: Ophthalmology Product Name: EM-100
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2020
Details:
U.S. Food and Drug Administration (FDA) regarding its decision on the review of EM-100. EM-100’s Generic Drug User Fee Act (GDUFA) target action date was August 10th.
Lead Product(s): Ketotifen Fumarate
Therapeutic Area: Ophthalmology Product Name: EM-100
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 11, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
